CytomX Therapeutics (CTMX) Competitors $2.25 -0.14 (-5.86%) Closing price 04:00 PM EasternExtended Trading$2.27 +0.02 (+0.93%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. OCS, VIR, NAGE, ANAB, AVBP, MNMD, IOVA, AMLX, CRMD, and TNGXShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Oculis (OCS), Vir Biotechnology (VIR), Niagen Bioscience (NAGE), AnaptysBio (ANAB), ArriVent BioPharma (AVBP), Mind Medicine (MindMed) (MNMD), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), CorMedix (CRMD), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors Oculis Vir Biotechnology Niagen Bioscience AnaptysBio ArriVent BioPharma Mind Medicine (MindMed) Iovance Biotherapeutics Amylyx Pharmaceuticals CorMedix Tango Therapeutics Oculis (NASDAQ:OCS) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk. Do analysts recommend OCS or CTMX? Oculis currently has a consensus target price of $35.33, suggesting a potential upside of 95.21%. CytomX Therapeutics has a consensus target price of $5.33, suggesting a potential upside of 137.04%. Given CytomX Therapeutics' higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of OCS or CTMX? 22.3% of Oculis shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer OCS or CTMX? In the previous week, CytomX Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for CytomX Therapeutics and 1 mentions for Oculis. Oculis' average media sentiment score of 1.89 beat CytomX Therapeutics' score of 1.54 indicating that Oculis is being referred to more favorably in the media. Company Overall Sentiment Oculis Very Positive CytomX Therapeutics Very Positive Is OCS or CTMX more profitable? CytomX Therapeutics has a net margin of 28.22% compared to Oculis' net margin of -13,788.70%. Oculis' return on equity of -92.95% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,788.70% -92.95% -70.03% CytomX Therapeutics 28.22%-553.71%32.21% Which has more volatility & risk, OCS or CTMX? Oculis has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Which has higher valuation & earnings, OCS or CTMX? CytomX Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K1,013.14-$97.43M-$2.64-6.86CytomX Therapeutics$138.10M1.31$31.87M$0.484.69 SummaryCytomX Therapeutics beats Oculis on 11 of the 14 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$192.68M$3.02B$5.70B$9.56BDividend YieldN/A2.40%4.71%4.06%P/E Ratio4.6921.0028.1919.94Price / Sales1.31331.94459.6596.38Price / Cash6.6042.5736.3258.72Price / Book-225.008.138.295.77Net Income$31.87M-$55.06M$3.25B$259.21M7 Day Performance-5.86%0.88%0.21%-0.80%1 Month PerformanceN/A15.04%8.71%9.81%1 Year Performance58.45%2.54%32.76%14.37% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.1439 of 5 stars$2.25-5.9%$5.33+137.0%+59.3%$192.68M$138.10M4.69170Positive NewsHigh Trading VolumeOCSOculis2.2236 of 5 stars$17.50flat$35.33+101.9%+54.0%$764.09MN/A-6.632VIRVir Biotechnology3.4848 of 5 stars$5.52+2.0%$30.25+448.0%-48.8%$763.09M$74.21M-1.31580NAGENiagen Bioscience1.4107 of 5 stars$9.68-4.7%$13.22+36.6%N/A$762.49M$99.60M56.94120ANABAnaptysBio1.8299 of 5 stars$26.17+1.0%$42.38+61.9%-28.3%$761.54M$91.28M0.00100News CoverageUpcoming EarningsAVBPArriVent BioPharma2.1613 of 5 stars$21.55-2.3%$39.29+82.3%-6.5%$754.39MN/A0.0040Positive NewsMNMDMind Medicine (MindMed)2.0012 of 5 stars$9.95+12.0%$25.50+156.3%+3.0%$751.72MN/A-7.7140News CoverageHigh Trading VolumeIOVAIovance Biotherapeutics4.5315 of 5 stars$2.49+11.7%$12.22+390.9%-68.1%$744.67M$164.07M0.00500High Trading VolumeAMLXAmylyx Pharmaceuticals3.38 of 5 stars$8.21-1.6%$11.75+43.1%+305.6%$743.44M$87.37M0.00200Positive NewsCRMDCorMedix2.7397 of 5 stars$10.94+0.7%$17.14+56.7%+163.9%$736.58M$43.47M49.3630TNGXTango Therapeutics1.8673 of 5 stars$6.77flat$10.50+55.1%-31.6%$733.80M$42.07M-5.5590News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Oculis Competitors Vir Biotechnology Competitors Niagen Bioscience Competitors AnaptysBio Competitors ArriVent BioPharma Competitors Mind Medicine (MindMed) Competitors Iovance Biotherapeutics Competitors Amylyx Pharmaceuticals Competitors CorMedix Competitors Tango Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
